Alterity Therapeutics Limited (ATHE) reported that Non-Executive Director Lawrence Gozlan will present at the ASX SMIDcaps Conference on September 23, 2026 at 1:55 p.m. AEST, with access to registration and an archived webcast available via the company’s website under Investors: Events and Presentations.
Alterity describes itself as a clinical stage biotechnology company developing disease modifying therapies for neurodegenerative diseases, with a focus on Multiple System Atrophy and related Parkinsonian disorders. The company is preparing to initiate a Phase 3 pivotal trial of its lead asset ATH434 in MSA, following clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data from an open label Phase 2 trial in advanced MSA.
ALTERITY THERAPEUTICS LTD (ATHE) director Peter Ashley Marks reported related transactions on August 31, 2026 through Lampam Pty Ltd. An entity associated with him bought 47,620 ordinary shares at $0.50 per share, bringing its indirect holdings to 191,340 ordinary shares, and disposed of 47,620 listed options with a $0.50 exercise price expiring August 31, 2026.
ALTERITY THERAPEUTICS LTD (ATHE) reported that Chief Executive Officer and director David Allen Stamler recorded a disposition involving derivative securities tied to the company’s ordinary shares. On August 31, 2026, he reported a transaction in 47,620 listed options expiring August 31, 2026 at a reported price of $0.50 per option, with 47,620 underlying ordinary shares. Following the transaction, this listed option position is shown as 0 derivative securities held directly.
Alterity Therapeutics Limited (ATHE) reports that it has completed the issue of 8,400,000 fully paid ordinary shares to MST Financial Services Pty Ltd and various sub-underwriters. The shares were issued pursuant to an underwriting agreement relating to Alterity’s ATHO class of listed options exercisable at A$0.50 each on or before August 31, 2026.
The company has provided a cleansing notice under section 708A(5)(e) of the Corporations Act 2001 (Cth), which facilitates secondary trading of these newly issued shares in compliance with Australian securities law.
ALTERITY THERAPEUTICS LTD (ATHE) reports that CEO David Stamler, M.D., will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on September 11, 2026 at 10:20 a.m. ET, with a live and archived webcast available via the company’s investor website.
Alterity is a clinical stage biotechnology company developing disease modifying therapies for neurodegenerative diseases, focusing on Multiple System Atrophy and related Parkinsonian disorders. The company is preparing to initiate a Phase 3 pivotal trial of its lead asset ATH434, which has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open label Phase 2 trial in advanced MSA.